Lakefront Biotherapeutics

As of June 30, 2026, Lakefront Biotherapeutics carries a market capitalization of 1.80B, placing it among publicly traded companies globally. Its enterprise value stands at -750.08M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Lakefront Biotherapeutics's next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Lakefront Biotherapeutics has 65.66M shares outstanding.

As of June 30, 2026, Lakefront Biotherapeutics trades at a trailing price-to-earnings ratio of 2.65. The price-to-sales ratio is 1.60, and the price-to-book ratio stands at 0.48.

As of June 30, 2026, Lakefront Biotherapeutics maintains a current ratio of 32.84, meaning it holds 32.8x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Lakefront Biotherapeutics posted a return on equity (ROE) of 20.20, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 16.64, measuring how efficiently the asset base is converted into earnings. The company generates approximately 2.20M in revenue per employee across its workforce of 515.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.19 indicates how many times Lakefront Biotherapeutics sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Lakefront Biotherapeutics recorded an income tax benefit of -19.07M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 659.92M, leaving 681.64M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on September 23, 2026, Lakefront Biotherapeutics's stock has declined approximately 4.48% over the past 52 weeks. The 50-day moving average sits at 34.98, while the 200-day moving average is 77.55.

Over the twelve months ended June 30, 2026, Lakefront Biotherapeutics generated 1.13B in revenue and converted that into 681.64M in net income, yielding earnings per share of 10.14. EBITDA reached 461.05M, while operating income came in at 696.80M.

As of June 30, 2026, Lakefront Biotherapeutics holds 2.56B in cash and equivalents against 7.27M in total debt, resulting in a net debt position of -155.32M. Total book value stands at 3.73B, with working capital of 2.56B providing operational flexibility.

Lakefront Biotherapeutics produced -259.24M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -5.26M in capital expenditures, free cash flow totaled -264.50M - equivalent to -4.02 per share.

Over the twelve months ended June 30, 2026, Lakefront Biotherapeutics posted a gross margin of 97.45, reflecting its pricing power and cost economics. The operating margin of 61.57 and net profit margin of 60.23 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -14.40: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.39, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Lakefront Biotherapeutics shareholders.

As of June 30, 2026, Lakefront Biotherapeutics has an Altman Z-Score of 13.12, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.